{
    "clinical_study": {
        "@rank": "149794", 
        "arm_group": [
            {
                "arm_group_label": "FA", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive oral folic acid pill 1 mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (FA Arm)."
            }, 
            {
                "arm_group_label": "FA+Ca", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive oral folic acid pill 1 mg+ calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects(FA+Ca arm)."
            }, 
            {
                "arm_group_label": "Ca", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive oral calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (Ca Arm)."
            }, 
            {
                "arm_group_label": "blank control group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients receive oral placebo once daily for 36 months in the absence of unacceptable toxicity or any other adverse effects."
            }
        ], 
        "brief_summary": {
            "textblock": "Folic acid (FA) and its derivatives (folate) which play a role in nucleotide synthesis and\n      methylation reactions as well as calcium and vitamin D are assumed to be effective in the\n      prevention of colorectal polyps and Colorectal cancer (CRC). The aim of this study is to\n      investigate the roles of FA as well as calcium and vitamin D in the prevention of CRC."
        }, 
        "brief_title": "Study of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Colorectal cancer (CRC) affects approximately one million people each year with a five-year\n      survival rate of 62% . Considerable interest has recently been focused on the relationship\n      between the chemoprevention of colorectal polyps/CRA and CRC. Therefore, the use of\n      nutritional compounds which are usually less afflicted with the risk of severe side effects\n      for colorectal adenoma (CRA) prevention and health maintenance is an emerging field."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  individuals aged 50-80 years\n\n          -  Patients had undergone complete colonoscopy with no adenoma found\n\n          -  Those who voluntarily sign the consent form after being fully informed and\n             understanding the purpose and procedures of the study, characters of the disease,\n             effect of medications, methods of related examinations, and potential risk/benefits\n             of the study\n\n        Exclusion Criteria:\n\n          -  Patients who are hypersensitive or intolerant to the drugs\n\n          -  Patients who are intolerant to another colonoscopy examination\n\n          -  Pregnant women, woman during breast-feeding period, or women with expect pregnancy\n\n          -  Patients with diabetes mellitus, severe heart or renal disease\uff0cor cancer history\n\n          -  Patients with malignant neoplasm, or suspicious colorectal cancer\n\n          -  Patients who are not able to cooperate\n\n          -  Individuals who are involved in designing, planning or performing this experiment\n\n          -  Patients with medical conditions who are not appropriate to participate the study\n\n          -  Patients who are take aspirin or cyclooxygenase 2 inhibitor \uff08COX2\uff09."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "2400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066688", 
            "org_study_id": "SQ2011SF12RJ", 
            "secondary_id": "SQ2011SF12-20121010"
        }, 
        "intervention": [
            {
                "arm_group_label": "FA", 
                "description": "Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.", 
                "intervention_name": "folic acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "FA+Ca", 
                "description": "Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .", 
                "intervention_name": "folic acid  calcium  vitamin D3", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ca", 
                "description": "calcium 1200mg/d + vitamin D3 250 IU/d daily supplements", 
                "intervention_name": "calcium", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium, Dietary", 
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Folic Acid", 
                "Vitamins", 
                "Vitamin B Complex", 
                "Hematinics"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 18, 2014", 
        "location": {
            "contact": {
                "email": "jingyuanfang2007@126.com", 
                "last_name": "Jing-yuan Fang, MD,Ph D."
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "zip": "200001"
                }, 
                "name": "Renji Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomize Controlled Trial of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer", 
        "other_outcome": {
            "measure": "Changes in routine blood count, urine and stool routine test, liver and kidney functions", 
            "safety_issue": "Yes", 
            "time_frame": "baseline and 3 years"
        }, 
        "overall_contact": {
            "email": "fangjingyuan_new@163.com", 
            "last_name": "Jing-Yuan Fang, M.D.,Ph D."
        }, 
        "overall_contact_backup": {
            "email": "yingxuanchen71@126.com", 
            "last_name": "Ying-xuan Chen, M.D.,Ph D."
        }, 
        "overall_official": {
            "affiliation": "Shanghai Jiao Tong University School of Medicine", 
            "last_name": "Jing-yuan Fang, MD., Ph D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary objective of this study is to investigate the incidence of colorectal adenoma (CRA) after Folic acid, calcium and vitamin D intervention.", 
            "safety_issue": "No", 
            "time_frame": "baseline and 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066688"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Jiao Tong University School of Medicine", 
            "investigator_full_name": "Jing-yuan Fang, MD, Ph. D", 
            "investigator_title": "Director of Department of Gastroenterology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "the incidence of advanced colorectal adenoma (A-CRA) after Folic acid, calcium and vitamin D intervention.", 
                "safety_issue": "No", 
                "time_frame": "baseline and 3 years"
            }, 
            {
                "measure": "changes in serum calcium", 
                "safety_issue": "Yes", 
                "time_frame": "baseline and 3 years"
            }, 
            {
                "measure": "changes in serum FA", 
                "safety_issue": "Yes", 
                "time_frame": "baseline and 3 years"
            }, 
            {
                "measure": "the incidence of colorectal cancer (CRC) after Folic acid, calcium and vitamin D intervention.", 
                "safety_issue": "No", 
                "time_frame": "baseline and 3 years"
            }, 
            {
                "measure": "changes in clinical symptoms scores (positive  immunochemical fecal occult blood test (iFOBT), diarrhea, or constipation et al)", 
                "safety_issue": "No", 
                "time_frame": "baseline and 3 years"
            }, 
            {
                "measure": "differences in Histological types of CRA OR CRC", 
                "safety_issue": "No", 
                "time_frame": "baseline and 3 years"
            }
        ], 
        "source": "Shanghai Jiao Tong University School of Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "Ministry of Science and Technology of the People\u00b4s Republic of China", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Shanghai Jiao Tong University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}